



Salzburg  
Cancer  
Research  
Institute

## SALZBURG BREAST CANCER TALK 02. – 03.03.2018

### MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY

#### FRIDAY, 2<sup>th</sup> MARCH

**13:00 – 14:00** Come together and Lunch Buffet

**14:00** Welcome and introduction

14:10 Current evidence of immunotherapy in breast cancer

Richard Greil (*Salzburg*)

Peter Schmid (*London*)

**14:30–16:00** Immunogenicity I: Tumor - immune cell interaction

*Chair: Richard Greil (Salzburg), Karen Willard-Gallo (Brussels)*

14:30 The role of B-cells and Tertiary Lymphoid structures (TLS)

Karen Willard-Gallo (*Brussels*)

14:50 The yin yang of innate immunity, inflammation and cancer

Alberto Mantovani (*Milan*)

15:10 Computing and probing cancer immunity

Zlatko Trajanoski (*Innsbruck*)

15:30 Panel discussion

**16:00 – 16:30** Coffee break

**16:30 – 18:00** Immunogenicity II: Triggers and Modulators

*Chair: Fabrice André (Paris), Richard D. Kennedy (Belfast)*

16:30 Influence on immunogenicity by driver mutations

Fabrice André (*Paris*)

16:50 Influence on immunogenicity by the microbioma

Maria Rescigno (*Milan*)

17:10 Influence on immunogenicity by DNA damage response deficiency

Richard D. Kennedy (*Belfast*)

17:30 Panel discussion

**18:30** Dinner

#### SATURDAY, 3<sup>th</sup> MARCH

**08:30 – 10:00** Monitoring and prediction of response to immunotherapy

*Chair: Fritz Aberger (Salzburg), Gabriel Rinnerthaler (Salzburg)*

08:30 Change of immune infiltrate during treatment\*

Roberto Salgado (*Brussels*)

09:00 Monitoring anti-tumor immune response in the blood\*

Alexander Egle (*Salzburg*)

09:30 Prediction of response to PD-1/PD-L1 blockade\*

Marleen Kok (*Amsterdam*)

10:00 Neoantigene heterogeneity\*

Marco Gerlinger (*London*)

**10:30 – 11:00** Coffee break

**11:00 – 12:30** Combination strategies with checkpoint-inhibitors

*Chair: Richard Greil (Salzburg), Simon Gampenrieder (Salzburg)*

11:00 Combination with chemotherapy

Giuseppe Curigliano (*Milan*)

11:20 Combination with vaccination

Richard Greil (*Salzburg*)

11:40 Combination with radiotherapy

Udo Gaipl (*Erlangen*)

12:00 Panel discussion

**12:30** Lunch Buffet

\* Discussion after lecture

The Pitter Event Center  
Rainerstrasse 6 – 8  
5020 Salzburg

[www.imlauer.com](http://www.imlauer.com)



Free WLAN-Access:  
CP event\_open



**Prof. Dr. Richard Greil**  
Head of the IIIrd Medical Department  
University Hospital Salzburg  
Paracelsus Medical University  
Salzburg Cancer Research Institute (SCRI)  
Cancer Cluster Salzburg (CCS)  
Salzburg, Austria

**Prof. Peter Schmid FRCP MD PhD**  
Centre Lead | Centre for Experimental  
Cancer Medicine  
Director, Breast Cancer, St Bartholomew  
Hospital London  
London, United Kingdom

**Karen Willard-Gallo MD PhD**  
Head, Molecular Immunology Laboratory  
Institut Jules Bordet  
Université Libre de Bruxelles  
Brussels, Belgium

**Prof. Alberto Mantovani MD**  
Humanitas University  
Scientific Director  
Istituto Clinico Humanitas IRCCS  
Milan, Italy

**Prof. Dipl.-Ing. Dr. Zlatko Trajanoski**  
Biocenter, Division for Bioinformatics  
Medical University of Innsbruck  
Innsbruck, Austria

**Prof. Fabrice André MD PhD**  
Research Director, Head of INSERM  
Unit U981  
Institut Gustave Roussy  
Department of Medical Oncology  
Villejuif, France

**Prof. Maria Rescigno PhD**  
Director of Dendritic cell biology and  
immunotherapy Unit  
Director Immunotherapy programme,  
European Institute of Oncology and  
Dipartimento di Scienze della Salute,  
Università di Milano  
Milan, Italy

**Prof. Richard Kennedy MD PhD**  
McClay Professor of Medical Oncology  
Queen's University of Belfast  
Global VP and Medical Director Almac  
Diagnostics

**Prof. Dr. Fritz Aberger**  
Molecular Cancer and Stem Cell Research  
Lab Department of Molecular Biology  
University of Salzburg  
Salzburg, Austria

**Dr. Gabriel Rinnerthaler**  
IIIrd Medical Department  
University Hospital Salzburg  
Paracelsus Medical University  
Salzburg Cancer Research Institute (SCRI)  
Cancer Cluster Salzburg (CCS)  
Salzburg, Austria

**Dr. Roberto Salgado**  
Breast Cancer Translational Research  
Laboratory, Department of Pathology, GZA  
Institut Jules Bordet, Brussels  
Antwerp, Belgium

**Priv.-Doz. Dr. Alexander Egle**  
IIIrd Medical Department  
University Hospital Salzburg  
Paracelsus Medical University  
Salzburg Cancer Research Institute (SCRI)  
Cancer Cluster Salzburg (CCS)  
Salzburg, Austria

**Marleen Kok MD PhD**  
Research Fellow Cancer Immunotherapy  
of the Dutch Cancer Society  
The Netherlands Cancer Institute  
Amsterdam, the Netherlands

**Dr. Marco Gerlinger**  
Translational Oncogenomics Laboratory  
Centre for Evolution and Cancer  
Institute of Cancer Research  
London, United Kingdom

**Dr. Simon P. Gampenrieder**  
IIIrd Medical Department  
University Hospital Salzburg  
Paracelsus Medical University  
Salzburg Cancer Research Institute (SCRI)  
Cancer Cluster Salzburg (CCS)  
Salzburg, Austria

**Giuseppe Curigliano MD PhD**  
New Drugs and Early Drug Development  
for Innovative Therapies Division  
European Institute of Oncology  
Milan, Italy

**Prof. Dr. Udo Gaipl**  
Head of Radiation Immunobiology  
Universitätsklinikum Erlangen  
Department of Radiation Oncology  
Erlangen, Germany

**Organization:**

Richard Greil  
Gabriel Rinnerthaler  
Simon P. Gampenrieder

**Salzburg Cancer Research Institute (SCRI) with**  
Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)  
[www.limcr.at](http://www.limcr.at) and  
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)  
[www.cccit.at](http://www.cccit.at)

in cooperation with the  
**Cancer Cluster Salzburg** | [www.cancercluster-salzburg.at](http://www.cancercluster-salzburg.at) and **AGMT gemeinnützige GmbH** | [www.agmt.at](http://www.agmt.at)



Salzburg  
Cancer  
Research  
Institute

CCCIT  
Center for  
Clinical Cancer  
and Immunology Trials

LIMCR  
Laboratory for  
Immunological and  
Molecular Cancer Research



CANCER  
CLUSTER  
SALZBURG  
[WWW.CANCERCLUSTER-SALZBURG.AT](http://WWW.CANCERCLUSTER-SALZBURG.AT)

**AGMT**

ARBEITSGEMEINSCHAFT  
MEDIKAMENTÖSE  
TUMORTHERAPIE

Kindly supported by: AstraZeneca



NOVARTIS  
ONCOLOGY



Bristol-Myers Squibb

This event will be requested for  
**12 DFP points**